Linked Life Data

16796788

Source:http://linkedlifedata.com/resource/pubmed/id/16796788

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-6-26
pubmed:abstractText
Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC: mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epiderman growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients with increased severity significantly correlated with improved medium overall survival (OS). Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1533-0028
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
29-31
pubmed:dateRevised
2008-5-30
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
pubmed:affiliation
CIG Medical Group, LP, Dallas, TX, USA.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III